The primary
end points and the secondary
end point were no significant differences between two groups with the in-hospital and long-term follow-up.
In the early days of H.264, years before the idea of AVC for streaming had been ratified, there were significant interoperability issues between H.263 and H.264 videoconferencing
end points. These issues were both codec incompatibilities as well as processing power incompatibilities.
Lower the machine needle down into the fabric precisely at the dart
end point, just one thread away from the fold (8).
However, although statistical analysis of the appropriate data can eliminate mutual confounding, care is required to address the most sensitive
end points that may be sensitive to risk and not benefit.
The patient is not in a position to know in advance what welfare or disability is or, in other words, what the
end point of rehabilitation could be.
They were randomized to one of two open-label antihypertensive treatment strategies featuring blinded
end point assessment: a [beta]-blocker with added diuretic as needed, or a calcium channel blocker plus an angiotensin converting enzyme inhibitor.
This acts to minimise the errors associated with the traditional indicators, which mask or blur the
end point due to the samples colouration, so accurate and reproducible analysis is assured.
Primary
end point results observed from the 100% patient enrollment point in the study's open-label phase are consistent with those observed at the 25% and 50% milestone assessments.
"This approval is the first to use the
end point of metastasis-free survival," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement.
Vaughan Clift, Ampio's Chief Regulatory Officer (CRO), has completed analysis of the primary
end point in the Optina clinical trial for DME diabetic macular oedema conducted at St Michael Diabetes Hospital in Toronto Canada.
M2 PHARMA-June 11, 2012-Ampio Pharmaceuticals Inc's CRO completes analysis of primary
end point in Optina(tm) clinical trial for Diabetic Macular Edema(C)2012 M2 COMMUNICATIONS
In the first trial (Trial 303), 21.2% and 19.4% of patients on the 145-mcgand 290-mcg doses, respectively, achieved the study's primary
end point of three or more complete spontaneous bowel movements (CSBMs) per week plus an increase of one or more CSBMs per week over baseline during at least 9 of the 12 study weeks.
